Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242343 | 1.00 | PARP1 (0.67) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL20544385 | 0.85 | PARP1 (0.55) | PARP1 | |
| SCHEMBL3388659 | 0.84 | PARP1 (0.71) | PARP1PRAP1 | |
| SCHEMBL8055652 | 0.84 | PARP1 (0.74) | PARP1 | |
| SCHEMBL8050461 | 0.84 | PARP1 (0.74) | PARP1 | |
| SCHEMBL2208157 | 0.84 | PARP1 (0.74) | PARP1 | |
| SCHEMBL4093910 | 0.84 | PARP1 (0.61) | PARP1PRAP1 | |
| SCHEMBL13007009 | 0.83 | PARP1 (0.72) | PARP1PRAP1 | |
| SCHEMBL863338 | 0.82 | PARP1 (0.92) | PARP1 | |
| SCHEMBL29408705 | 0.82 | PARP1 (0.92) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021108350-A1 | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20140363522-A1 | Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins | NIH - DEITR | 2014-12-11 | — | — | US | disclosed |
| US-8748470-B2 | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins | THE UNIVERSITY OF CHICAGO (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120289570-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS | NIH | 2012-11-15 | — | — | US | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2875/4885CYP3A4 1684/4885CYP2C9 2008/4885 |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2388/4885CYP3A4 1674/4885CYP2C9 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.